BioAge Labs, Inc. announced progress in their development pipeline, highlighting the advancement of their oral NLRP3 inhibitor BGE-102, with initial clinical data expected in the second half of 2025.
A major financing round completed in January has provided BioAge Labs with the capital necessary to fund its research initiatives through 2029. This financial cushion allows the biotechnology firm to ...
RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
Most of 2025 has been disappointing for BioAge Labs (NASDAQ: BIOA) shareholders, but things are looking up. During the week that ended Oct. 25, shares of the obesity drug developer soared by 46.6%.
BioAge Labs (NASDAQ: BIOA) is a small drugmaker whose shares have caught fire this year. The company has made clinical progress in the hottest therapeutic area in the industry right now: Weight ...
BioAge Labs is having its initial public offering today. The drug developer’s signature product, Azelaprag, isn’t yet on sale, but it is undergoing clinical trials in hopes it will one day be. What ...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit ...
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial ...
The latest price target for Bioage Labs (NASDAQ:BIOA) was reported by Morgan Stanley on December 8, 2025. The analyst firm set a price target for $12.00 expecting BIOA to fall to within 12 months (a ...
RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as ...
New York, New York--(Newsfile Corp. - March 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results